MFC

• CAT Number: I032211
• CAS Number: 575-04-2
• Molecular Formula: C11H7F3O3
• Molecular Weight: 244.17
• Purity: 95%
• Synonyms: MFC; 7-Methoxy-4-(trifluoromethyl)coumarin
• Solubility: To be determined
• Appearance: Solid powder
• Storage: −20°C
• IUPAC Name: 7-methoxy-4-(trifluoromethyl)-2H-chromen-2-one
• InChI: InChI=1S/C11H7F3O3/c1-16-6-2-3-7-8(11(12,13)14)5-10(15)17-9(7)4-6/h2-5H,1H3
• InChIKey: HAZHUELNIGDYQH-UHFFFAOYSA-N
• SMILES: O=C1OC2=C(C=CC(OC)=C2)C(C(F)(F)F)=C1

MFC（Cat No.:I032211）, serves as a fluorogenic substrate for cytochrome P450 enzymes (CYPs). When acted upon by CYPs, it undergoes enzymatic cleavage, releasing 7-hydroxy-4-(trifluoromethyl)coumarin (HFC). The fluorescence of HFC can be measured to quantify CYP activity. HFC exhibits maximum excitation and emission wavelengths of 410 nm and 510 nm, respectively. This property makes MFC a useful tool in studying and assessing the activity of cytochrome P450 enzymes in various biological and pharmaceutical research applications.

Reference

1: Santes-Palacios R, Olguín-Reyes S, Hernández-Ojeda SL, Camacho-Carranza R, Espinosa-Aguirre JJ. Differential inhibition of naringenin on human and rat cytochrome P450 2E1 activity. Toxicol In Vitro. 2020 Dec;69:105009. doi: 10.1016/j.tiv.2020.105009. Epub 2020 Sep 29. PMID: 33007396.
2: Shah MB, Liu J, Huo L, Zhang Q, Dearing MD, Wilderman PR, Szklarz GD, Stout CD, Halpert JR. Structure-Function Analysis of Mammalian CYP2B Enzymes Using 7-Substituted Coumarin Derivatives as Probes: Utility of Crystal Structures and Molecular Modeling in Understanding Xenobiotic Metabolism. Mol Pharmacol. 2016 Apr;89(4):435-45. doi: 10.1124/mol.115.102111. Epub 2016 Jan 29. PMID: 26826176; PMCID: PMC4809303.
3: Mooiman KD, Goey AK, Huijbregts TJ, Maas-Bakker RF, Beijnen JH, Schellens JH, Meijerman I. The in-vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity. J Pharm Pharmacol. 2014 Sep;66(9):1339-46. doi: 10.1111/jphp.12259. Epub 2014 Apr 15. PMID: 24730468.
4: Wilderman PR, Gay SC, Jang HH, Zhang Q, Stout CD, Halpert JR. Investigation by site-directed mutagenesis of the role of cytochrome P450 2B4 non-active-site residues in protein-ligand interactions based on crystal structures of the ligand-bound enzyme. FEBS J. 2012 May;279(9):1607-20. doi: 10.1111/j.1742-4658.2011.08411.x. Epub 2011 Nov 25. PMID: 22051155; PMCID: PMC3911823.
5: Makaji E, Trambitas CS, Shen P, Holloway AC, Crankshaw DJ. Effects of cytochrome P450 inhibitors on the biotransformation of fluorogenic substrates by adult male rat liver microsomes and cDNA-expressed rat cytochrome P450 isoforms. Toxicol Sci. 2010 Feb;113(2):293-304. doi: 10.1093/toxsci/kfp255. Epub 2009 Oct 25. PMID: 19858067.
6: Oezguen N, Kumar S, Hindupur A, Braun W, Muralidhara BK, Halpert JR. Identification and analysis of conserved sequence motifs in cytochrome P450 family 2. Functional and structural role of a motif 187RFDYKD192 in CYP2B enzymes. J Biol Chem. 2008 Aug 1;283(31):21808-16. doi: 10.1074/jbc.M708582200. Epub 2008 May 21. PMID: 18495666; PMCID: PMC2490781.
7: Szotáková B, Baliharová V, Lamka J, Nozinová E, Wsól V, Velík J, Machala M, Neca J, Soucek P, Susová S, Skálová L. Comparison of in vitro activities of biotransformation enzymes in pig, cattle, goat and sheep. Res Vet Sci. 2004 Feb;76(1):43-51. doi: 10.1016/s0034-5288(03)00143-7. PMID: 14659728.
8: Egnell AC, Eriksson C, Albertson N, Houston B, Boyer S. Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther. 2003 Dec;307(3):878-87. doi: 10.1124/jpet.103.054999. Epub 2003 Oct 13. PMID: 14557374.